ARS Pharmaceuticals, Inc. (SPRY)
4.23
-0.33
(-7.24%)
USD |
NASDAQ |
Oct 09, 16:00
4.24
+0.01
(+0.24%)
After-Hours: 20:00
ARS Pharmaceuticals Free Cash Flow : -196.60M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -196.60M |
| March 31, 2026 | -175.32M |
| December 31, 2025 | -171.20M |
| September 30, 2025 | -86.02M |
| June 30, 2025 | -53.38M |
| March 31, 2025 | -21.06M |
| December 31, 2024 | 12.98M |
| September 30, 2024 | -46.03M |
| June 30, 2024 | -44.23M |
| March 31, 2024 | -53.61M |
| December 31, 2023 | -59.44M |
| September 30, 2023 | -30.24M |
| Date | Value |
|---|---|
| June 30, 2023 | -23.15M |
| March 31, 2023 | -13.45M |
| December 31, 2022 | -7.772M |
| September 30, 2022 | 9.007M |
| June 30, 2022 | -4.487M |
| March 31, 2022 | -12.33M |
| December 31, 2021 | -17.62M |
| September 30, 2021 | -57.62M |
| June 30, 2021 | -46.08M |
| March 31, 2021 | -36.69M |
| December 31, 2020 | -32.11M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Capricor Therapeutics, Inc. | -129.78M |
| Sionna Therapeutics, Inc. | -76.21M |
| Nektar Therapeutics | -234.03M |
| Ardelyx, Inc. | -17.92M |
| Kyntra Bio, Inc. | -38.06M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -60.93M |
| Cash from Investing (Quarterly) | 41.57M |
| Cash from Financing (Quarterly) | 3.197M |
| Free Cash Flow Per Share (Quarterly) | -0.6135 |
| Free Cash Flow to Equity (Quarterly) | -61.08M |
| Free Cash Flow to Firm (Quarterly) | -58.45M |
| Free Cash Flow Yield | -46.89% |